Demographic Factors May Impact Pain Management Referrals in SCLC/NSCLCMarch 15th 2023
Factors including age, gender, and facility type may influence the likelihood of pain specialist referrals for lung cancer, suggesting a need for multidisciplinary pain management in this patient population.
Efforts are Underway to Tackle Immunotherapy Resistance in Refractory RCCMarch 14th 2023
Increasing cancer antigen presentation as well as working with tumor cells in and delivering novel cells to the microenvironment may help in overcoming mechanisms of immune checkpoint inhibitor resistance in refractory renal cell carcinoma.
Pembrolizumab/Chemo Appears to Improve Survival in Advanced MesotheliomaMarch 13th 2023
The final analysis of the phase 2/3 CCTG IND.227/KEYNOTE-483 trial identifies a statistically significant survival benefit with pembrolizumab and chemotherapy vs chemotherapy alone in the first-line setting for patients with unresectable advanced or metastatic malignant pleural mesothelioma.
Ipilimumab Yields ‘Limited Effect’ in Refractory Kidney Cancer SubtypeMarch 12th 2023
Ipilimumab monotherapy does not appear effective in driving complete responses in refractory renal cell carcinoma despite yielding some progression-free survival intervals, according to an expert from the University of Texas Southwestern Medical Center.
Expert Highlights Armamentarium of Advanced Kidney Cancer TherapiesMarch 11th 2023
An expert from the University of Texas Southwestern Medical Center discusses several phase 3 clinical trials supporting the use of various single-agent and combination immunotherapy regimens for advanced kidney cancer.
BXCL701/Pembrolizumab Yields Durable Responses in Prostate Cancer SubtypeMarch 10th 2023
All patients with platinum-resistant, small-cell neuroendocrine prostate cancer who responded to treatment with BXCL701 plus pembrolizumab were microsatellite stable and/or tumor mutational burden–low with a low probability of response to pembrolizumab.
FDA ODAC Votes in Favor of Polatuzumab Vedotin in Previously Untreated DLBCLMarch 10th 2023
Polatuzumab vedotin-piiq plus R-CHP was found to produce clinical efficacy in phase 3 POLARIX trial in patients with previously untreated diffuse large B-cell lymphoma, leading to an 11-to-2 vote from the FDA’s Oncologic Drug Advisory Committee.
Switch Maintenance Darolutamide Prolongs rPFS in Metastatic Prostate CancerMarch 9th 2023
Data from a phase 2 placebo-controlled trial may support darolutamide switch maintenance therapy following at least 1 androgen receptor pathway inhibitor and taxane chemotherapy in patients with metastatic castration-resistant prostate cancer.
Neoadjuvant/Adjuvant Durvalumab Yields Meaningful EFS Benefit in NSCLCMarch 9th 2023
Final analyses for pathologic response appear consistent with previous reports from the phase 3 AEGEAN trial evaluating neoadjuvant durvalumab and chemotherapy plus adjuvant durvalumab monotherapy in resectable non–small cell lung cancer.
FDA Accepts Remestemcel-L BLA Resubmission for Pediatric Acute GVHDMarch 8th 2023
The FDA initially issued a complete response letter for remestemcel-L in pediatric steroid-refractory acute graft-versus-host disease in October 2020, citing a need for an additional randomized, controlled trial to confirm the agent’s efficacy.
Abatacept Combo May Reduce Immunotherapy-Related Myotoxicity in CancerMarch 8th 2023
Abatacept plus ruxolitinib and screenings for concomitant respiratory muscle failure may be effective in reducing the rate of mortality related to immune checkpoint inhibitor–associated myocarditis among patients with cancer.
Expert Highlights Tolerability and Safety of Ziftomenib in Phase 1 TrialMarch 7th 2023
An expert from Duke Health says that patients with NPM1-mutatant relapsed/refractory acute myeloid leukemia did not experience any significant safety signals following treatment with ziftomenib.
Camrelizumab Yields ‘Impressive’ Activity in Head & Neck Cancer SubtypeMarch 7th 2023
Camrelizumab plus apatinib demonstrates impressive anti-tumor activity in a pretreated population with recurrent or metastatic nasopharyngeal carcinoma, although further research is needed, according to an expert from Memorial Sloan Kettering Cancer Center.
TKI Treatment Breaks May Not Impact Outcomes in Renal Cell CarcinomaMarch 7th 2023
Patients with advanced clear cell renal cell carcinoma are “unlikely” to experience a clinically meaningful decrease in overall survival following planned treatment cessation with a tyrosine kinase inhibitor.
FDA Approves Pegfilgrastim Biosimilar to Mitigate Febrile Neutropenia From ChemoMarch 6th 2023
A prefilled autoinjector presentation of pegfilgrastim-cbqv, a pegfilgrastim biosimilar, has been approved by the FDA for patients with cancer undergoing chemotherapy who may experience febrile neutropenia.